Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Drug Companies Developing Hepatitis C Medicines for People Who Do Not Respond to Interferon Therapy

November 9, 2004

Drug company representatives and researchers attending the American Association for the Study of Liver Diseases' recent conference in Boston presented data on current and emerging treatments for hepatitis C virus, particularly those who do not respond to traditional treatment, Investor's Business Daily reports. According to CDC, 3.9 million U.S. residents are infected with HCV, and the disease leads to between 10,000 and 12,000 deaths annually from liver failure. Currently, the most common treatment -- pegylated interferon administered with ribavirin -- boosts patients' immune systems but does not directly attack HCV. Normally, patients take interferon three times daily for 48 weeks, and physicians monitor the patients for an additional 24 weeks. If the patient shows no sign of the virus after that time, they are considered to be cured. However, the treatment only is effective for about half of the people who take it, according to Investor's Business Daily. Therefore, the number of people suffering from "chronic" HCV infection is growing, representing a "growth market," according to Dan Welch, CEO of InterMune, a biotech company that is working on developing a drug to treat nonresponders, Investor's Business Daily reports. Welch said that the "poor response rate" for interferon gives smaller biotech companies an opportunity to develop new drugs, according to Investor's Business Daily. Both large and small biotech companies believe that the "hot area" of HCV treatment research is studying whether protease inhibitors -- which are now used to treat HIV -- could be effective in treating HCV, according to Investor's Business Daily (Reeves, Investor's Business Daily, 11/8).

Back to other news for November 9, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement